Literature DB >> 20956598

Activity of deferasirox in Mucorales: influences of species and exogenous iron.

Russell E Lewis1, Georgios N Pongas, Nathaniel Albert, Ronen Ben-Ami, Thomas J Walsh, Dimitrios P Kontoyiannis.   

Abstract

Differences in deferasirox susceptibility among members of the order Mucorales are unknown. Here we show that Cunninghamella bertholletiae (four isolates) and Mucor species (five isolates) display higher deferasirox MICs and minimal fungicidal concentrations compared to Rhizopus species (six isolates). Exogenous iron further attenuated the deferasirox susceptibility of Mucorales isolates with low MICs. Vital staining revealed damage to subapical compartments in susceptible strains.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20956598      PMCID： PMC3019624          DOI： 10.1128/AAC.00792-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Authors:  Antonio Piga; Renzo Galanello; Gian Luca Forni; Maria Domenica Cappellini; Raffaella Origa; Antonietta Zappu; Guido Donato; Elena Bordone; Antonella Lavagetto; Laura Zanaboni; Romain Sechaud; Nicola Hewson; John M Ford; Herbert Opitz; Daniele Alberti
Journal:  Haematologica       Date:  2006-07       Impact factor: 9.941

2.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 3.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

4.  The effect of deferoxamine on different zygomycetes.

Authors:  J R Boelaert; M de Locht; Y J Schneider
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

Review 5.  Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

6.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; A Fothergill; J Peter; M G Rinaldi; T J Walsh
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus.

Authors:  M de Locht; J R Boelaert; Y J Schneider
Journal:  Biochem Pharmacol       Date:  1994-05-18       Impact factor: 5.858

9.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
  10 in total
  12 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 3.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

4.  Iron starvation induces apoptosis in Rhizopus oryzae in vitro.

Authors:  Fazal Shirazi; Dimitrios P Kontoyiannis; Ashraf S Ibrahim
Journal:  Virulence       Date:  2015       Impact factor: 5.882

5.  Siderophore production by pathogenic mucorales and uptake of deferoxamine B.

Authors:  Gérald Larcher; Marylène Dias; Bienvenue Razafimandimby; Danielle Bomal; Jean-Philippe Bouchara
Journal:  Mycopathologia       Date:  2013-08-28       Impact factor: 2.574

6.  Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series.

Authors:  Maria N Chitasombat; Pimjai Niparuck
Journal:  Infect Dis Rep       Date:  2018-09-25

7.  Antibacterial activities of iron chelators against common nosocomial pathogens.

Authors:  Mitchell G Thompson; Brendan W Corey; Yuanzheng Si; David W Craft; Daniel V Zurawski
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

8.  Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo.

Authors:  Régis A Zanette; Paula E R Bitencourt; Dimitrios P Kontoyiannis; Rafael A Fighera; Mariana M Flores; Glaucia D Kommers; Priscila S Silva; Aline Ludwig; Maria B Moretto; Sydney H Alves; Janio M Santurio
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

9.  Iron and Acinetobacter baumannii Biofilm Formation.

Authors:  Valentina Gentile; Emanuela Frangipani; Carlo Bonchi; Fabrizia Minandri; Federica Runci; Paolo Visca
Journal:  Pathogens       Date:  2014-08-18

10.  Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis.

Authors:  Samuel A Shelburne; Nadim J Ajami; Marcus C Chibucos; Hannah C Beird; Jeffrey Tarrand; Jessica Galloway-Peña; Nathan Albert; Roy F Chemaly; Shashank S Ghantoji; Lisa Marsh; Naveen Pemmaraju; Michael Andreeff; Elizabeth J Shpall; Jennifer A Wargo; Katayoun Rezvani; Amin Alousi; Vincent M Bruno; Phillip A Futreal; Joseph F Petrosino; Dimitrios P Kontoyiannis
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.